Next Article in Journal
Improved Prediction of miRNA-Disease Associations Based on Matrix Completion with Network Regularization
Next Article in Special Issue
Towards a Comprehensive Understanding of UA-ADRCs (Uncultured, Autologous, Fresh, Unmodified, Adipose Derived Regenerative Cells, Isolated at Point of Care) in Regenerative Medicine
Previous Article in Journal
MeCP2 and Chromatin Compartmentalization
Previous Article in Special Issue
Spermatogonial Stem Cells for In Vitro Spermatogenesis and In Vivo Restoration of Fertility
Open AccessArticle

Human AlphoidtetO Artificial Chromosome as a Gene Therapy Vector for the Developing Hemophilia A Model in Mice

1
Institute of Cytology, Russian Academy of Sciences, 4 Tikhoretsky Ave., St-Petersburg 194064, Russia
2
Developmental Therapeutics Branch, National Cancer Institute, Bethesda, MD 20892, USA
3
Institute of Translational Biomedicine, St-Petersburg State University, 7–9, Universitetskaya Emb., St-Petersburg 199034, Russia
*
Author to whom correspondence should be addressed.
Authors equally contributed to the work.
Cells 2020, 9(4), 879; https://doi.org/10.3390/cells9040879
Received: 28 February 2020 / Revised: 28 March 2020 / Accepted: 30 March 2020 / Published: 3 April 2020
(This article belongs to the Special Issue Stem Cell-based Therapy and Disease Modeling)
Human artificial chromosomes (HACs), including the de novo synthesized alphoidtetO-HAC, are a powerful tool for introducing genes of interest into eukaryotic cells. HACs are mitotically stable, non-integrative episomal units that have a large transgene insertion capacity and allow efficient and stable transgene expression. Previously, we have shown that the alphoidtetO-HAC vector does not interfere with the pluripotent state and provides stable transgene expression in human induced pluripotent cells (iPSCs) and mouse embryonic stem cells (ESCs). In this study, we have elaborated on a mouse model of ex vivo iPSC- and HAC-based treatment of hemophilia A monogenic disease. iPSCs were developed from FVIIIY/− mutant mice fibroblasts and FVIII cDNA, driven by a ubiquitous promoter, was introduced into the alphoidtetO-HAC in hamster CHO cells. Subsequently, the therapeutic alphoidtetO-HAC-FVIII was transferred into the FVIIIY/– iPSCs via the retro-microcell-mediated chromosome transfer method. The therapeutic HAC was maintained as an episomal non-integrative vector in the mouse iPSCs, showing a constitutive FVIII expression. This study is the first step towards treatment development for hemophilia A monogenic disease with the use of a new generation of the synthetic chromosome vector—the alphoidtetO-HAC. View Full-Text
Keywords: human artificial chromosome (HAC); hemophilia; coagulation factor VIII; alphoidtetO-HAC; induced pluripotent stem cells (iPSCs); microcell-mediated chromosome transfer (MMCT); cell reprogramming human artificial chromosome (HAC); hemophilia; coagulation factor VIII; alphoidtetO-HAC; induced pluripotent stem cells (iPSCs); microcell-mediated chromosome transfer (MMCT); cell reprogramming
Show Figures

Figure 1

MDPI and ACS Style

Ponomartsev, S.V.; Sinenko, S.A.; Skvortsova, E.V.; Liskovykh, M.A.; Voropaev, I.N.; Savina, M.M.; Kuzmin, A.A.; Kuzmina, E.Y.; Kondrashkina, A.M.; Larionov, V.; Kouprina, N.; Tomilin, A.N. Human AlphoidtetO Artificial Chromosome as a Gene Therapy Vector for the Developing Hemophilia A Model in Mice. Cells 2020, 9, 879.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop